Title:
DRUG FOR TREATING HUMAN TUMOR BY ERF3A TARGETED PROTEIN DEGRADATION MECHANISM
Document Type and Number:
WIPO Patent Application WO/2024/066454
Kind Code:
A1
Abstract:
Provided are a targeted protein degradation compound TPB-L-E3B, and a synthetic method therefor and use thereof. Such compounds can be used for treating human tumor diseases by means of an eRF3a targeted degradation mechanism, and have shown great potential for treating such diseases in in-vitro experiments, especially for treating diseases such as prostate cancer, ovarian cancer, liver cancer, cervical cancer, leukemia, and breast cancer.
More Like This:
| WO/1998/041509 | METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME |
| JP2928385 | [Title of Invention] A novel tetracyclic compound |
| WO/1997/019929 | POLYCYCLIC COMPOUNDS |
Inventors:
YU GUANGLIANG (CN)
ZHONG KAI (CN)
CHEN YAO (CN)
HAN LIUQUAN (CN)
TIAN JIAHUI (CN)
ZHANG CHANGZHOU (CN)
HU ZHENXING (CN)
XU PING (CN)
MAO SHUJUN (CN)
ZHONG KAI (CN)
CHEN YAO (CN)
HAN LIUQUAN (CN)
TIAN JIAHUI (CN)
ZHANG CHANGZHOU (CN)
HU ZHENXING (CN)
XU PING (CN)
MAO SHUJUN (CN)
Application Number:
PCT/CN2023/098569
Publication Date:
April 04, 2024
Filing Date:
June 06, 2023
Export Citation:
Assignee:
SUZHOU DEGEN BIO MEDICAL CO LTD (CN)
International Classes:
C07D221/18; A61K31/435; A61K47/55; A61P35/00; C07D401/14
Domestic Patent References:
| WO1995000147A1 | 1995-01-05 |
Foreign References:
| CN106458993A | 2017-02-22 | |||
| CN110612294A | 2019-12-24 | |||
| CN112262134A | 2021-01-22 | |||
| US5994362A | 1999-11-30 |
Download PDF: